Study Evaluating AGG-523 in Subjects With Osteoarthritis

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the effect of AGG-523 administration on biomarkers related to osteoarthritis. Safety and tolerability of AGG-523 will also be assessed.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

Inclusion:

• Mild to moderate Osteoarthritis of the target knee.

• Subjects must be generally healthy but enrolled with stable chronic illness if well controlled.